Oncotype DX AR-V7 Nucleus Detect Test AR-V7 ADVOCATE TOOLKIT
|
|
- Arlene Webb
- 5 years ago
- Views:
Transcription
1 Oncotype DX AR-V7 Nucleus Detect Test AR-V7 ADVOCATE TOOLKIT or
2 Advocate TOOLKIT We re pleased to be able to share these AR-V7 resources with you video, graphics, social media templates, and blog. Feel free to take these materials and modify as you feel appropriate for your audiences. If you have any questions or would like additional resources, please do not hesitate to let us know! Bernadette and Sara
3 Video Click on the YouTube video below to watch and share on your favorite social media platforms. What is the Oncotype DX AR-V7 Nucleus Detect Test
4 Graphics Click to download the graphics below and use on your favorite social media platforms.
5 Social Media Feel free to edit and use these sample posts and share on your social media channels. Did you know a simple blood test can help you find the best treatment for your #metastatic castration-resistant #prostatecancer? Find out more at bit.ly/odxarv7 Did you know #prostatecancer patients can become resistant to hormone therapies over time? The #Oncotype DX AR-V7 Nucleus Detect test can help you and your doctor determine the treatment that s best for you. Check out this video: youtu.be/mouxuoku4bi DYK: AR-V7 (+) status in #metastatic castration-resistant #prostatecancer indicates more aggressive cancers and that patients may benefit more from chemotherapy. Learn more at bit.ly/odxarv7 DYK: AR-V7 (-) status in #metastatic castration-resistant #prostatecancer indicates patients may have more benefit from new/additional anti-androgen therapy. Learn more at bit.ly/odxarv7 #Metastatic castration-resistant #prostatecancer now have tools to help determine the best treatment option for them. Find out more about the #Oncotype DX AR-V7 Nucleus Detect test youtu.be/mouxuoku4bi
6 Blog Feel free to share the information from the sample blog to create your own blog, newsletter article or online feature. For men with metastatic castration resistant prostate cancer (mcrpc), deciding between treatment options can be complicated. A number of therapies are now available for these patients, including androgen receptor (AR)-targeted drugs as well as chemotherapy, but knowing which treatment will provide the most benefit to which patient has been a challenge. However, with the recent availability of the Oncotype DX AR-V7 Nucleus Detect test, men with mcrpc now can get more clarity. Today, mcrpc patients are often first treated with AR-targeted drugs such as XTANDI or ZYTIGA ¹. Unfortunately, over time, many patients acquire resistance, meaning they will no longer receive benefit from the drug and need to consider another treatment. Traditionally, it s been difficult to predict what type of treatment will be better for an individual patient do you go to another AR-drug or switch to chemotherapy? With the Oncotype DX AR-V7 Nucleus Detect test, patients have that answer. The test is a simple blood draw and detects the presence of AR-V7 protein in circulating tumor cells (CTCs) that cause AR-drugs to be significantly less effective compared to traditional chemotherapy. If AR-V7 protein is found (a positive test result), the patient is more likely to benefit from switching to chemotherapy. If AR-V7 protein is not found (a negative test result), the patient may benefit from new/additional AR therapy. For all prostate cancer patients, it s important to take an active role in your care. Talk to your doctor. Ask questions. Learn about all your options so you can make the best treatment decision for your cancer. To find out more about the Oncotype DX AR-V7 Nucleus Detect test, visit ¹Xtandi is a registered trademark of Astellas Pharma, Inc. Zytiga is a registered trademark of Johnson and Johnson.
7 For More INFORMATION If you have questions or need additional information, please contact the Patient Advocacy team at Genomic Health: Follow us on social media! facebook.com/genomichealth twitter.com/genomichealth youtube.com/genomichealth GHI60023_0918
Genomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationAn educational guide from Genomic Health
Active Surveillance or Immediate Treatment? The Oncotype DX Prostate Cancer Assay helps you and your doctor choose with confidence. For more information, visit OncotypeDX.com. An educational guide from
More informationFOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey
FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER Discover a test that can help you on your treatment journey Jim G. Oncotype DX GPS patient navigating prostate cancer since 2014 Not all prostate
More informationWHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE CANCER PATIENTS
WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE CANCER PATIENTS There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn
More informationWHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE 1 CANCER PATIENTS
WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE 1 CANCER PATIENTS There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn
More informationHave you been recently diagnosed with stage II or stage III colon cancer?
Have you been recently diagnosed with stage II or stage III colon cancer? Jen D. A busy mother of two and active community volunteer. Dan C. Diagnosed at age 43 An educational An educational guide guide
More informationHave you been recently diagnosed with DCIS?
Have you been recently diagnosed with DCIS? Jen D. A busy mother of two and active community volunteer. Jen D. A busy mother of 2 and active community volunteer. *DCIS = Ductal carcinoma in situ AnAn educational
More informationTHE 3 NEW SOCIAL MEDIA STRATEGIES TO CONNECT WITH LOCAL PATIENT ADVOCATES TO BOOST SITE ENROLLMENT
THE 3 NEW SOCIAL MEDIA STRATEGIES TO CONNECT WITH LOCAL PATIENT ADVOCATES TO BOOST SITE ENROLLMENT PEOPLE DON T CARE HOW MUCH YOU KNOW UNTIL THEY KNOW HOW MUCH YOU CARE.. -TEDDY ROOSEVELT TODAY S DISCUSSION
More informationClinical Policy: Enzalutamide (Xtandi) Reference Number: CP.CPA.203 Effective Date: Last Review Date: 02.19
Clinical Policy: (Xtandi) Reference Number: CP.CPA.203 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationWHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE1 CANCER PATIENTS
WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE1 CANCER PATIENTS There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationPOSITIVE CHMP OPINION FOR XTANDI (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER 1
POSITIVE CHMP OPINION FOR XTANDI (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER 1 Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant
More informationStraumann Patient Pro. The plus for your business
Straumann Patient Pro The plus for your business How patients take a more active role in their care. Nowadays, information is just a few clicks away. Though the dentist is still a very important information
More informationOncotype DX tools User Guide
Oncotype DX tools User Guide This guide provides an overview of the data and quick access to the Oncotype DX tools Oncotype DX tools offers two quantitative calculator tools that may be used together with
More informationRadical prostate surgery?
Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your
More informationZytiga. Zytiga (abiraterone acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.28 Subject: Zytiga Page: 1of 5 Last Review Date: March 13, 2014 Zytiga Description Zytiga (abiraterone
More informationPPI Sponsored Golf Tourney, August 2nd. To register, go to Kitsap Cancer Services for more information.
Issue 2 / July 2014 Greetings! Welcome to another edition of the Peninsula Prostate Institute (PPI) Newsletter. In this installment we will cover a variety of prostate cancer topics ranging from the latest
More informationJeffrey Bruno/Aleteia (CC BY-SA 4.0)
1 Jeffrey Bruno/Aleteia (CC BY-SA 4.0) In preparation for Pope Francis Special Audience for the HD community in solidarity with South America on May 18 th, we want as many people as possible to know about
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationWelcome to the Webinar: Lions Let s Get Ready for Diabetes Alert Day!
Welcome to the Webinar: Lions Let s Get Ready for Diabetes Alert Day! Welcome! Lions Let s Get Ready for Diabetes Alert Day! LCI Staff LCI Staff with you today: Marilee Kadar, Manager Debbie O Malley,
More informationWhat is the Oncotype DX test?
Patient & Family Guide 2018 What is the Oncotype DX test? www.nscancercare.ca What is the Oncotype DX test? Information for women diagnosed with early-stage breast cancer What is the Oncotype DX test?
More informationHeart Disease and Stroke. You re the Cure. You re the Cure A Guide for Advocates
Heart Disease and Stroke. You re the Cure. You re the Cure A Guide for Advocates Contents 3 AHA Mission Statement 3 Overview: You re the Cure Advocate and Contact Information 4 Ways to Get Involved 5 How
More informationBe Your Donors Favorite Charity: Why Engagement Matters. Thursday, January 31 st 2013
Be Your Donors Favorite Charity: Why Engagement Matters Thursday, January 31 st 2013 Presenter: Donna Wilkins, Founder and CEO, Charity Dynamics At Charity Dynamics, we help nonprofits leverage technology
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationU.S. FDA Approves New Indication for the Use of XTANDI (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
Astellas Contact: Medivation Contact: Tyler Marciniak Rick Bierly Director, Communications and Advocacy Chief Financial Officer (847) 736-7145 (415) 543-3470 tyler.marciniak@astellas.com Anne Bowdidge
More informationSee Submission for References.
Guideline Page and Request PROS-1 External submission from Myriad Genetic Laboratories, Inc. requesting addition of the following statement as a distinct step immediately to the right of life expectancy
More informationSummary A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER TREATMENT OPTIONS
A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OCTOBER 2018 Summary CASTRATION-RESISTANT PROSTATE CANCER Prostate cancer is the second most common cause of cancer
More informationBreastCancerAdvisor by DR. SILVANA MARTINO JANUARY 2012
Dear Readers, I wish each of you a happy and healthy 2012. Now that the new year is here, each of us must make the most of it. Many years ago I saw a sign that said, In life you don t always get what you
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationHello e-communications Toolkit
Hello e-communications Toolkit Thank you for supporting the Hello campaign. In this booklet you will find information on Hello which you can use in electronic communications with your audiences. Please
More informationGETTING CONNECTED INTERPRETER RESOURCES ON THE WORLD WIDE WEB
GETTING CONNECTED INTERPRETER RESOURCES ON THE WORLD WIDE WEB WWW.ISDOUTREACH.ORG RESOURCES FOR YOU FROM OUTREACH RESOURCES FROM WWW.ISDOUTREACH.ORG Fingerspelling: http://www.aslfingerspelling.org Classifiers:
More informationoperaamerica.org/operaweek #OperaWeek
operaamerica.org/operaweek #OperaWeek 1 NATIONAL OPERA WEEK About National Opera Week ABOUT NATIONAL OPERA WEEK PROGRAM OVERVIEW What is National Opera Week? National Opera Week (October 27 November 5)
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationpcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of
More informationimage Empower Yourself With Knowledge for managing advanced prostate cancer
image Empower Yourself With Knowledge 7 Principles for managing advanced prostate cancer Where the mind goes... the body follows. Bill Blair, founder of Mets Mavericks, an Us TOO support group formed to
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationWhen starting a new line of therapy for your metastatic breast, colorectal, and prostate 1 cancer patients
When starting a new line of therapy for your metastatic breast, colorectal, and prostate 1 cancer patients There is uncertainty whether their prognosis will improve It can take as long as 3 months to learn
More informationJUMPSTART YOUR IMMUNE SYSTEM TO ATTACK YOUR ADVANCED PROSTATE CANCER
JUMPSTART YOUR IMMUNE SYSTEM TO ATTACK YOUR ADVANCED PROSTATE CANCER Talking to your doctor about For more information visit www.provenge.com Please see inside front cover and page 7 for Important Safety
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationRecruiting Tips, Tools & Incentives. Tuesday, September 16, 2014
Recruiting Tips, Tools & Incentives Tuesday, September 16, 2014 Today s Moderators Sara Sanders SNA State Affiliate Relations Manager Rachel Lightcap SNA Membership Manager Questions & Answers Type your
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More information17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom
My Biases Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom I am a member of the specialist group of the Prostate
More informationGETTING CONNECTED 7/1/16 RESOURCES FROM RESOURCES FOR YOU FROM OUTREACH
GETTING CONNECTED INTERPRETER RESOURCES ON THE WORLD WIDE WEB WWW.ISDOUTREACH.ORG RESOURCES FOR YOU FROM OUTREACH RESOURCES FROM WWW.ISDOUTREACH.ORG Fingerspelling: http://www.aslfingerspelling.org Classifiers:
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Technology Appraisal Review Proposal paper Review of TA259; Abiraterone for castration-resistant metastatic prostate cancer following
More informationONLINE BRANDING GUIDE
ONLINE BRANDING GUIDE American Academy of Dental Sleep Medicine Online Branding Guide Page 1 Table of Contents Introduction Page 2 Using the Toolkit Page 2 AADSM Membership Certificate Page 2 Website Materials
More informationEducator Navigation Guide
Decoding Breast Cancer Virtual Lab Educator Navigation Guide Decoding Cancer Nav Guide 2 Introduction In this virtual lab, students test tissue samples from different patients with breast cancer in order
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationCDC s New Milestone Tracker: There s an App for That!
CDC s New Milestone Tracker: There s an App for That! Katie K. Green, MPH, CHES Health Communication Specialist Karnesha Slaughter, MPH Health Communication Specialist CDC s Empowering parents and other
More informationWelcome to Dr. Judy Salerno! Komen Research Highlights Shared with Affiliate Community. Table of Contents:
Page 1 of 6 Share Past Issues Komen Research Updates Affiliates hear UCLA research, Zumba Global Research Grant, Research Highlights and more! Welcome to Dr. Judy Salerno! Today we officially welcome Judy
More informationCancer de la prostate: best of 2016
Cancer de la prostate: best of 2016 Dr Christophe Massard GR2016, 3 DEC 2016 Disclosure Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech,
More informationOUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationLost Mothers Event Toolkit
Lost Mothers Event Toolkit YOUR STEP-BY-STEP GUIDE TO SPARKING COMMUNITY CONVERSATION AND CHANGE ON MATERNAL HEALTH A Contents INTRODUCTION 1 GUIDELINES 2 GETTING STARTED... 3-4 Setting Goals Collaborating
More informationFrom Patient to Patient Advocate
From Patient to Patient Advocate How Sharing Our Stories Can Lead Us to Discover Our Passion and Purpose Sara Wyen www.bloodclotrecovery.net A blood clot in a large vein, usually in a person s arm or
More informationLearn more about Susan G. Komen
Learn more about Susan G. Komen Download the PDF version Dear Public Service Director, Those living with Stage IV metastatic breast cancer face a different reality, a sobering reality that Stage IV breast
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More information2-1-1 Teen HELPLINE. Toolkit for Agencies, Professionals, & Supporters Teen HELPLINE is a service of the Institute for Human Services, Inc.
2-1-1 Teen HELPLINE Toolkit for Agencies, Professionals, & Supporters 2-1-1 Teen HELPLINE is a service of the Institute for Human Services, Inc. WELCOME! Dear Supporter of Youth, Welcome to the 2-1-1 Teen
More informationCafé Le Brain Welcome Montreal! Bienvenue Montréal! February 17, 2015 / 17 Février 2015
Café Le Brain Welcome Montreal! Bienvenue Montréal! February 17, 2015 / 17 Février 2015 Recording This webinar is being recorded and will be posted as a public video on YouTube. If you are using a webcam
More informationHAVE YOU BEEN recently DIAGNOSED with stage II or stage III colon cancer?
To learn more about the Oncotype DX Colon Cancer Test, please visit www. oncotypedx.com and talk to your health care team. For insurance, financial aid or other questions about the Oncotype DX test, please
More informationEverything you need to stay connected
Everything you need to stay connected GO WIRELESS Make everyday tasks easier Oticon Opn wireless accessories are a comprehensive and easy-to-use range of devices developed to improve your listening and
More informationHealth Smart Virginia - Sample Lesson Plan
Health Smart Virginia - Sample Lesson Plan Grade 10 ATOD Use Prevention Unit 6 SOLs: 10.1.g Research trends in teen use/abuse of alcohol, tobacco, other drugs their impact on the community. 10.1.h Evaluate
More informationMANAGING ADVANCED PROSTATE CANCER
MANAGING ADVANCED PROSTATE CANCER DETERMINING YOUR DISEASE STATE WHAT IS? Whether you ve been living with prostate cancer for years or are newly diagnosed, you have advanced prostate cancer if: 1. The
More informationThe Murtha Cancer Center 2nd Annual Cancer Research Seminar Walter Reed National Military Medical Center Bethesda, MD June 23, 2014
The Murtha Cancer Center 2nd Annual Cancer Research Seminar Walter Reed National Military Medical Center Bethesda, MD June 23, 2014 Center for Prostate Disease Research (CPDR) Overview and Research Highlights
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More information1-800-CHILDREN ( ) Resource Map Marketing Tool Kit
Healthy Childhoods Last a Lifetime 1-800-CHILDREN (1-800-244-5373) Resource Map Marketing Tool Kit The 1-800-CHILDREN Helpline has a new companion tool to help professionals find support for families they
More informationSEPSIS CAMPAIGN MEMBER AND PARTNER TOOLKIT. 155 E. Broad St., Suite 301 Columbus, OH t f ohiohospitals.
SEPSIS CAMPAIGN MEMBER AND PARTNER TOOLKIT The Ohio Hospital Association s mission is to collaborate with member hospitals and health systems to ensure a healthy Ohio. Contents OHA is committed to reducing
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationLUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology
LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers
More informationWelcome! Getting to Know You Session
Welcome! Getting to Know You Session Photos! Send to education@nhpco.org Technical support: nhpco@commpartners.com or 1-800-274-9390 Conference Objectives Define/describe models for successful community-based
More informationNational Drug and Alcohol Facts Week: Shatter the Myths in Your School. October 23, 2018
National Drug and Alcohol Facts Week: Shatter the Myths in Your School October 23, 2018 We Believe In the transformational power of the health and education intersection Webinar Archives The State of
More informationEngaging a Healthier Life: Evaluating Social Media in Health Promotion. February 2013
Engaging a Healthier Life: Evaluating Social Media in Health Promotion February 2013 Today What is social media/social networking? What is Northern Health doing? Health care social media best practices
More informationThe Current Prostate Cancer Landscape
A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer
More informationFUNDRAISING KIT INDIVIDUALS, COMMUNITY AND WORKPLACE
FUNDRAISING KIT INDIVIDUALS, COMMUNITY AND WORKPLACE help raise the alarm #MAYDAYS2018 #ITCOSTME ABOUT THE CAMPAIGN Did you know 1 in 3 people have had to go into debt to treat their eating disorder? That
More informationKIRKPATRICK TRAINING EVALUATION DOESN T HAVE TO BE AS FORMAL AS YOU THINK
KIRKPATRICK TRAINING EVALUATION DOESN T HAVE TO BE AS FORMAL AS YOU THINK Wendy Kirkpatrick and Jim Kirkpatrick, PhD Thursday, January 11, 2018 Training Magazine Network Trademark and Copyright Warning
More informationWhy do you take prednisone with zytiga
Мобильный портал WAP версия: wap.altmaster.ru Why do you take prednisone with zytiga Apr 14, 2016. However, when prednisone is given with Zytiga, it's given for a different. Also, if you would like to
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationOutline. Outline. Phillip G. Febbo, MD. Genomic Approaches to Outcome Prediction in Prostate Cancer
Genomic Approaches to Outcome Prediction in Prostate Cancer Phillip G. Febbo, MD Duke Institute for Genome Science and Policy Department of Medicine Department of Molecular Genetics and Microbiology Duke
More informationBuild Your Online Brand
2/12/ 7:04:27 PM Build Your Online Brand James Nellis Please discard all your trash as you leave! Thank you. Please complete an evaluation for this session. Use any mobile device! www.evalfr.com Download
More informationred Go Red For Women American Heart Association Have Faith in Heart Toolkit Take Action at GoRedForWomen.org rojo rojo rojo red rojo red rojo rojo
American Heart Association Go Red For Women Have Faith in Heart Toolkit Take Action at GoRedForWomen.org Have Faith in Heart Let s unite to prevent heart disease and stroke. It s time to Go Red For Women.
More informationAdvocating for Reduced. Breastfeeding Disparities: The Los Angeles
Breastfeeding Disparities: The Los Angeles Arissa Palmer, MHS, CLEC Katie Waters-Smith, IBCLC, LCCE August 14, 2018 No disclosures Disclosures This presentation does not constitute legal advice. 1 Objectives
More informationUtilization of OncoType DX Test for
Utilization of OncoType DX Test for Breast Cancer in the Community Setting XC Wu, XR Li, V Petkov, MC Hsieh, M Loch, PA Andrews, VW Chen 2016 NAACCR Annual Conference June 8, 2016 Background Chemotherapy
More informationSocial Media Toolkit. Safety Week 2018
Social Media Toolkit Safety Week 2018 Tools Overall Theme Overall Messaging Social Goals Social Voice Platforms & Hashtags Sample Posts Templates Visual Resources Action Steps About Safety Week (Big Picture)
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More informationIntroduction to Marketing
Introduction to Marketing 1 What Is LEAP? A structured yet flexible post-stroke education program for stroke survivors and caregivers Developed by healthcare professionals Register to access all program
More informationYONSA (abiraterone acetate) oral tablet ZYTIGA (abiraterone acetate) oral tablet
ZYTIGA (abiraterone acetate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMANAGING ADVANCED PROSTATE CANCER
MANAGING ADVANCED PROSTATE CANCER DETERMINING YOUR DISEASE STATE WHAT IS? Whether you ve been living with prostate cancer for years or are newly diagnosed, you have advanced prostate cancer if: 1. The
More informationThank you for being a partner in this important endeavor to provide moms and babies with a natural and healthy start.
Introduction On behalf of the U.S. Department of Health and Human Services (HHS), thank you for participating in our new campaign, It s Only Natural. The local community plays a critical role in offering
More informationpcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of
More informationInnovative Audience Outreach:
Innovative Audience Outreach: Education through e-learning and Animation Biddy Smith, RN, BSN Network Task Lead for Special Projects Mitzi Vince Communications Specialist Quality Insights QIN-QIO 3 Covers
More informationIcd 10 metastatic castration resistant prostate cancer
Icd 10 metastatic castration resistant prostate cancer The Borg System is 100 % Icd 10 metastatic castration resistant prostate cancer Loss of cancer suppressor genes, early in the prostatic carcinogenesis,
More informationThanks. Connect. You Might Also Like. Thank you for downloading my product. I truly appreciate your support and look forward to hearing your feedback.
Thanks Thank you for downloading my product. I truly appreciate your support and look forward to hearing your feedback. Connect You can connect with me and find many free activities and strategies over
More informationHuman castration videos
Human castration videos The Borg System is 100 % Human castration videos Castration fantasy Question: Are there women who fantsise to castrate men? Are ther men who fantsise to be castrated by a woman?
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More information